Focus Areas
OPHTHALMOLOGICAL
DRY EYE DIAGNOSTICS
AXIM has developed and commercialized two FDA Cleared Diagnostic tests for Dye Eye Disease. The solutions are available now through exclusive partner Verséa Ophthalmic, LLC (“Verséa”), a subsidiary of Verséa Holdings, Inc.
COVID-19 & CANCER
AXIM Biotech has developed a rapid (10-minute) serological diagnostic test that detects SARS-CoV-2 neutralizing antibodies (Nabs) which are the antibodies needed to fight COVID-19 within the body. Additionally, using proprietary polyclonal antibodies in collaboration with world-renowned research and academic centers, AXIM has developed a prototype diagnostic test that measures levels of QSOX1-L in blood and filed for patent protection.
TEST DEVELOPMENT
INNOVATIVE DIAGNOSTIC SOLUTIONS
AXIM works with clients around the world on development of diagnostic solutions of all kinds for a variety of conditions and indications. For more information, please contact AXIM.